Ralliant Corporation (NYSE:RAL) Sees Significant Drop in Short Interest

Ralliant Corporation (NYSE:RAL) saw a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 3,692,056 shares, a decline of 35.5% from the July 30th total of 5,720,042 shares. Based on an average trading volume of 1,479,843 shares, the short-interest ratio is presently 2.5 days. Approximately 3.4% of the company’s stock are sold short.

Ralliant Stock Down 1.1%

Shares of NYSE:RAL traded down $0.67 during mid-day trading on Tuesday, hitting $61.06. 842,829 shares of the company traded hands, compared to its average volume of 1,653,742. The stock has a 50-day moving average price of $68.28 and a two-hundred day moving average price of $56.66. Ralliant has a 12-month low of $37.27 and a 12-month high of $75.41. The stock has a market cap of $6.76 billion, a P/E ratio of -5.63, a P/E/G ratio of 2.29 and a beta of 1.61. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.75.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The business had revenue of $567.80 million during the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, equities research analysts forecast that Ralliant will post 2.87 earnings per share for the current year.

Ralliant Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be issued a $0.05 dividend. The ex-dividend date is Tuesday, September 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant’s dividend payout ratio is currently -1.84%.

Analysts Set New Price Targets

RAL has been the subject of several research reports. Weiss Ratings restated a “sell (d)” rating on shares of Ralliant in a research note on Friday, July 31st. Royal Bank Of Canada upped their price target on Ralliant from $71.00 to $73.00 and gave the stock a “sector perform” rating in a research note on Friday, July 31st. TD Cowen increased their price target on Ralliant from $70.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Evercore assumed coverage on Ralliant in a research report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 target price on the stock. Finally, Truist Financial reaffirmed a “buy” rating and issued a $82.00 price objective (up from $68.00) on shares of Ralliant in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $75.70.

Insider Buying and Selling at Ralliant

In other Ralliant news, SVP Karen M. Bick sold 6,062 shares of Ralliant stock in a transaction on Monday, August 17th. The shares were sold at an average price of $72.00, for a total value of $436,464.00. Following the completion of the sale, the senior vice president directly owned 31,668 shares of the company’s stock, valued at approximately $2,280,096. The trade was a 16.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of Ralliant stock in a transaction on Friday, August 14th. The shares were sold at an average price of $71.79, for a total transaction of $928,675.44. Following the completion of the sale, the chief executive officer directly owned 251,967 shares of the company’s stock, valued at approximately $18,088,710.93. This trade represents a 4.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RAL. Allworth Financial LP lifted its position in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after buying an additional 293 shares in the last quarter. Rothschild Investment LLC increased its position in shares of Ralliant by 98.1% during the fourth quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock valued at $31,000 after acquiring an additional 303 shares during the last quarter. UMB Bank n.a. increased its position in shares of Ralliant by 49.6% during the fourth quarter. UMB Bank n.a. now owns 983 shares of the company’s stock valued at $50,000 after acquiring an additional 326 shares during the last quarter. Maryland State Retirement & Pension System lifted its holdings in Ralliant by 1.5% during the fourth quarter. Maryland State Retirement & Pension System now owns 21,940 shares of the company’s stock worth $1,117,000 after acquiring an additional 329 shares during the period. Finally, Dunhill Financial LLC purchased a new position in Ralliant in the second quarter worth $25,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.